Amlodipine maleate

Name: Amlodipine maleate
Brand: MedChemExpress
SKU: HY-B0317A
Rating: 5.0 (9 reviews)

Cat. No.: HY-B0317A Purity: 99.87%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Amlodipine maleate is a dihydropyridine calcium channel blocker, acts as an orally active antianginal agent. Amlodipine maleate blocks the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium. Amlodipine maleate can be used for the research of high blood pressure and cancer.

For research use only. We do not sell to patients.

Amlodipine maleate Chemical Structure

CAS No. : 88150-47-4

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent
10 mM * 1 mL in DMSO ready for reconstitution	USD 55	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 55	In-stock	Estimated Time of Arrival: December 31
Solid
500 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
1 g	USD 84	In-stock	Estimated Time of Arrival: December 31
5 g	USD 264	In-stock	Estimated Time of Arrival: December 31
10 g		Get quote
50 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Other Forms of Amlodipine maleate:

9 Publications Citing Use of MCE Amlodipine maleate

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

L-type calcium channel

In Vitro

Amlodipine maleate (20-40 μM; 48 h) reduces BrdU incorporation to 68.6% and 26.3% at concentrations of 20 and 30 μM in A431 cells, respectively^[3].
Amlodipine maleate (30 μM; pretreated for 1 h) significantly attenuates the uridine 5′-triphosphate (UTP)-induced increases of [Ca²⁺]_i in A431 cells^[3].
Amlodipine maleate (30 μM) inhibits the store-operated Ca²⁺influx evoked by Thapsigargin in Fluo-3-loaded cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Amlodipine maleate (5 mg/kg/day; s.c. for 2 weeks) significantly decreases systolic blood pressure (SBP) in VSMC ATP2B1 KO mice^[4].
Amlodipine maleate (10 mg/kg; i.p. once daily for 20 days) causes a significant retardation of tumor growth and prolongs the survival of A431 tumor-bearing mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	ATP2B1^loxP/loxP mice^[4]
Dosage:	5 mg/kg/day
Administration:	Subcutaneously implanted osmotic pump for 2 weeks
Result:	Significantly decreased the blood pressure.

Clinical Trial

Molecular Weight

524.95

Formula

C₂₄H₂₉ClN₂O₉

CAS No.

88150-47-4

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(C1=C(COCCN)NC(C)=C(C(OC)=O)C1C2=CC=CC=C2Cl)OCC.OC(/C=C\C(O)=O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 120 mg/mL (228.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9049 mL	9.5247 mL	19.0494 mL
5 mM	0.3810 mL	1.9049 mL	3.8099 mL
10 mM	0.1905 mL	0.9525 mL	1.9049 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.71 mg/mL (3.26 mM); Clear solution

This protocol yields a clear solution of ≥ 1.71 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (17.1 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.71 mg/mL (3.26 mM); Clear solution

This protocol yields a clear solution of ≥ 1.71 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (17.1 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.71 mg/mL (3.26 mM); Clear solution

This protocol yields a clear solution of ≥ 1.71 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (17.1 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.87%

Select Batch:

Data Sheet (280 KB) SDS (251 KB)

COA (256 KB) LCMS (266 KB)

Handling Instructions (2659 KB)

References

[1]. Yoshida J, et, al. Antitumor effects of amlodipine, a Ca2+ channel blocker, on human epidermoid carcinoma A431 cells in vitro and in vivo. Eur J Pharmacol. 2004 May 25;492(2-3):103-12. [Content Brief]

[2]. Okuyama Y, et, al. The effects of anti-hypertensive drugs and the mechanism of hypertension in vascular smooth muscle cell-specific ATP2B1 knockout mice. Hypertens Res. 2018 Feb;41(2):80-87. [Content Brief]

[3]. Kishen G. Bulsara, et al. Amlodipine.

[4]. Haria M, et al. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease [published correction appears in Drugs 1995 Nov;50(5):896]. Drugs. 1995;50(3):560-586. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9049 mL	9.5247 mL	19.0494 mL	47.6236 mL
	5 mM	0.3810 mL	1.9049 mL	3.8099 mL	9.5247 mL
	10 mM	0.1905 mL	0.9525 mL	1.9049 mL	4.7624 mL
	15 mM	0.1270 mL	0.6350 mL	1.2700 mL	3.1749 mL
	20 mM	0.0952 mL	0.4762 mL	0.9525 mL	2.3812 mL
	25 mM	0.0762 mL	0.3810 mL	0.7620 mL	1.9049 mL
	30 mM	0.0635 mL	0.3175 mL	0.6350 mL	1.5875 mL
	40 mM	0.0476 mL	0.2381 mL	0.4762 mL	1.1906 mL
	50 mM	0.0381 mL	0.1905 mL	0.3810 mL	0.9525 mL
	60 mM	0.0317 mL	0.1587 mL	0.3175 mL	0.7937 mL
	80 mM	0.0238 mL	0.1191 mL	0.2381 mL	0.5953 mL
	100 mM	0.0190 mL	0.0952 mL	0.1905 mL	0.4762 mL